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ABSTRACT 
Background: Malignant melanoma, generally described as incurable, is notoriously 
refractory to chemotherapy. The mechanisms contributing to this have not yet been 
defined and the contributions of drug efflux pumps, implicated in chemo-resistance of 
many other cancer types, have not been extensively investigated in melanoma. 
Methods: Here, expression of MDR1/P-gp and MRP-1 proteins was examined, by 
immunohistochemistry, in archival specimens from 134 melanoma patients. This 
included 92 primary tumours and 42 metastases. Results: Assessing all specimens, 
MRP-1 and MDR1/P-gp expression was found to be common, with the majority 
(81%) of melanomas expressing at least one of these efflux pumps. While there is 
significant association between expression of these pumps (P=0.007), MRP-1 was 
found to be the predominant (67% of cases) form detected. X2 analysis showed 
significant associations between expression of MRP-1 and/or MDR1/P-gp and the 
aggressive nature of this disease; specifically increased Breslow’s depth, Clark’s level 
and spread to lymph nodes. This association with aggressiveness and spread is further 
supported by the observation that a significantly higher percentage of metastases, than 
primary tumours, express MRP-1 (91% versus 57%; P<0.0001) and MDR1/P-gp 
(74% versus 50%; P=0.010). Conclusion: The predominant expression of these 
pumps and, in particular, MRP-1- suggests that they may be important contributors to 
the inherent aggressive and resistant nature of malignant melanoma. 
 
Keywords: malignant melanoma, multiple drug resistance, MDR1/P-gp, MRP-1, 
immunohistochemistry. 
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INTRODUCTION 
The incidence rate for cutaneous melanoma, which involves the malignant 
proliferation of melanocytes, is increasing faster than that of any other malignant 
disease, at an epidemic rate of 3% a year (Leiter and Garbe, 2008; Garbe and Leiter, 
2009). Over the last century, melanoma has progressed from being considered as a 
rare cancer to a situation where the lifetime risk of developing this disease is 1 in 50 
in many Western populations (Giblin and Thomas, 2007); with major socioeconomic 
consequences as a result of the high mortality rates associated with this metastatic 
disease (Meyle and Guldberg, 2009). Currently, approximately 133,000 new cases of 
melanoma are diagnosed worldwide each year. The NCI’s Surveillance Epidemiology 
and End Results estimates that in the US, in 2009 alone, 68,720 new cases of 
melanoma of the skin will be diagnosed and 8,650 people will die from this disease. 
 
Prognosis for patients with early-stage melanoma is very good and can often be cured 
by wide surgical excision. Metastatic disease, unfortunately, remains generally 
incurable and is largely resistant to current therapies, with a median survival time of 6 
to 9 months from diagnosis and a 5-year survival rate of 5.5% (Keller et al, 2006; 
Sarnaik and Weber, 2009). Biological therapies including IFN-alpha have 
demonstrated a real, but minimal, effect in malignant melanomas (Pavlick et al, 2003) 
and the effects of IL-2, as a treatment for malignant melanoma, are not yet clearly 
defined. High-dose bolus IL-2 produces some long-term remissions and is available 
for highly selected individuals, but is not suitable for most patients (Mohr et al, 2003; 
Agarwala, 2009). Chemotherapeutic therapy for melanoma has been attempted with 
the many chemotherapeutic drugs. Single agent chemotherapy, including dacarbazine, 
temozolomide, the nitrosureas (BCNU, CCNU and methyl CCNU), the vinca 
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alkaloids (vincristine, vinblastine and vindesine) cisplatin, paclitaxel and bleomycin 
have been used. Many of these are relatively well-tolerated (including dacarbazine, 
which now has FDA approval for this indication), but are associated with response 
rates of only 5-20% (Bhatia et al, 2009; Seetharamu et al, 2009). Multi-drug 
chemotherapy regimes have resulted in objective response rates, but do not extend 
survival and are associated with greater toxicity (Pawlik and Sondak, 2003; Nystrom 
et al, 2003; Tas et al, 2003; Bhatia et al, 2009). The limited response of malignant 
melanoma to chemotherapy is apparently due to the inherent drug refractory nature of 
this disease (Ichihashi and Kitajima, 2001; Colone et al, 2008). This has resulted in 
targeted therapies being fast-tracked through FDA approval e.g. Ipilimumab, which 
targets CTL4, and which is approved for metastatic and advanced melanoma. Such 
monoclonal antibodies are greatly more expensive than traditional chemotherapy and 
so an economic burden on many health systems. Unfortunately, they too may become 
of limited use due to the resistance nature of melanoma.  
 
There is some, albeit limited, evidence that expression of genes encoding membrane 
efflux pumps (ABC transport proteins), including MRP-1 (ABCC1) and MDR1/P-gp 
(ABCB1), may be associated with this chemo-resistance and so incurable nature of 
malignant melanomas. However, conflicting data exists on the details of the specific 
pump(s) involved. In a study of MRP-1 mRNA and protein expression in 40 
melanoma cell lines, Berger et al (1997) reported sensitivity to a broad range of 
chemotherapeutic drugs to inversely correlate with MRP-1 expression. Furthermore, 
analysis of mrp-1 and mdr-1 mRNA expression in 18 specimens from 8 melanoma 
patients’ tumours showed mrp-1 expression in the majority of pre-chemotherapy 
specimens; the levels of which were increased post-chemotherapy. mdr-1 mRNA was, 
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however, not detected in any of the specimens analysed (Ichihashi and Kitajima, 
2001). In keeping with this, based on studies of 21 primary malignant melanomas and 
37 metastases, Schadendorf et al (1995) reported 43% of both primary and metastatic 
tumours to express MRP-1, with a lack of detectable expression of MDR1/P-gp 
(except in 1 primary tumour) suggesting that the chemo-resistant nature of melanoma 
cells is unlikely to be mediated via MDR1/P-gp. Conversely, results from studies of 
human melanoma cultured cells (M14) suggested MDR1/P-gp, but not MRP-1, to be 
associated with the multi-drug resistant (MDR) phenotype (Molinari et al, 2000). In 
further studies of M14 cell line variants (specifically, MDR1/P-gp-positive drug-
resistant M14 ADR compared to MDR1/P-gp-negative drug sensitive M14 cells), 
members of the same research group have more recently reported MDR1/P-gp to 
linked to MAPK signalling and involved in melanoma cell migration and invasion 
(Colone et al, 2008).  
 
As outlined above, while studies of melanoma cell line models support an association 
between MDR1/P-gp and/or MRP-1 and the chemo-resistant, generally incurable, 
phenotype of malignant melanoma, studies of the prevalence of MDR1/P-gp and 
MRP-1 in melanoma specimens have been very limited and conflicting. To determine 
the potential involvement of these drug efflux pumps in the clinical setting, here we 
report results from a retrospective study of both MDR1/P-gp and MRP-1 protein 
expression and their associations with patients’ clinicopathological features (where 
possible) in 134 melanomas, including 92 primary tumours and 42 metastases.  
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MATERIALS AND METHODS 
 
Patients 
The patient group studied comprised of 134 consenting patients with malignant 
melanoma. All patients were diagnosed at St. Vincent’s University Hospital (SVUH), 
Dublin, between 1975 and 2002 and approval to conduct this study was granted by 
SVUH Ethics Committee. Formalin-fixed paraffin embedded material was available 
for all patients. Representative 4μm sections of tissue blocks were cut using a 
microtome, mounted onto poly-l-lysine coated slides and dried overnight at 37oC. 
Slides were stored at room temperature until required.  
 
Immunohistochemistry 
All steps were performed at room temperature unless otherwise indicated. Tissue 
sections were dewaxed in xylene (2 x 5 min.), rehydrated in grading alcohols 100%, 
90% and 70% (2 x 3 min. each), and placed in Tris Buffered Saline (TBS/0.05% 
Tween-20). Endogenous peroxidise activity was quenched by placing tissue sections 
in 3% (v/v) H2O2/distilled water for 5-6 min. All slides were blocked for non-specific 
staining with 20% normal rabbit serum (Dako, X-902)/TBS for 20 min. Primary 
antibodies were applied to each specimen. Specifically, anti-MDR1/P-gp clone 6/1C 
ascites (which we developed and previously extensively characterised as specific for 
MDR1/P-gp; Moran et al, 1997) was diluted 1:40 in TBS/0.05% Tween-20. Anti-
MRP-1 PA28(6) antibody (similarly, which we developed and extensively 
characterised as specific for MRP-1 (Connolly et al, 2001) was applied as neat 
supernatant. Primary antibodies were incubated overnight at 40C. Samples were then 
washed (3 x 5 min.) with TBS/0.05% Tween-20, followed by 30 min. incubation with 
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biotinylated secondary antibody diluted in TBS/0.05% Tween-20. Finally, following 
another 3 x 5 min. wash step, Vector SG substrate for peroxidise (Vector 
Laboratories, SK-4700) was applied for approx. 10 min. All slides were washed (3 x 5 
min.) in TBS/0.05% Tween-20. Tissue sections were then lightly counter-stained with 
Nuclear Fast Red (Vector Laboratories, H-3403). 
 
Following this, slides were dehydrated in grading alcohols 70%, 90% and 100% (2 x 
3 min.). Samples were then cleared in xylene and mounted in DPX (BDH, UK). 
Positive control normal kidney and lung tissue sections (using same experimental 
conditions) and negative control samples (in which primary antibody were replaced 
by 1x TBS/0.05% Tween-20) were included in all experiments. 
 
 
Immunohistochemical scoring 
MRP-1 and MDR1/P-gp immunohistochemical staining was scored (by Consultant 
Pathologist, Prof. Susan Kennedy) according to the percentage of cells showing 
specific immunoreactivity. A semi-quantitative measurement was used in which 
overall positivity of the tumour was assessed and a score of 1+ was given where up to 
25% of cells showed MRP-1 or MDR1/P-gp positive staining, as relevant; a score of 
2+ was given where >25-<50% cells showed positive staining; a score of 3+, where 
>50%-<75% of cells showed positive staining and a score of 4+, where >75% of cells 
showed positive staining. Scores of <1 were considered as negative; scores above 1 
were considered positive.  
 
Statistical analysis 
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Statistical analyses of the results were performed using SPSS 16.0 and InStat software 
packages. Descriptive statistics were used to summarise patient characteristics and 
statistical analysis of the results was performed using Pearson’s X2 test to investigate 
relationships between MDR1/P-gp and MRP-1 expression and clinicopathological and 
histopathological findings. Kaplan-Meier survival curves were established and were 
subsequently checked using the log-rank, Breslow and Tarone-ware tests (p-values 
represent log-rank, unless otherwise indicated) to assess the prognostic significance of 
MDR1/P-gp and MRP-1 protein expression. The data was analysed as a whole and as 
primary and metastases cohorts, respectively, and, where relevant, the data was also 
censored at 5 years. A value of p <0.05 was considered statistically significant. 
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RESULTS  
 
Patient Characteristics 
 
This study involved analysis of tumours from 134 patients with metastatic melanoma. 
Eighty-three of the patients were female; 51 were male. The patients ages ranged 
between 22 years and 104 years at the time of diagnosis (median age = 59 years). 
Ninety-two of the specimens available for analysis were primary tumours; 42 were 
secondary metastases. Further clinical characteristics of the patients are summarised 
in Table 1. 
 
MDR1/P-gp Expression 
MDR1/P-gp specific staining was observed in 57.5% (77/134) of the melanoma 
specimens analysed (a representative MDR1/P-gp positive tumour is shown in Figure 
1(A)). Specific staining was localised to cell membrane/cytoplasm. Approximately 
43% of tumours did not express MDR1/P-gp protein. MDR1/P-gp expression in 
primary and metastatic tumours, when analysed as separate cohorts, was 50% and 
73.8%, respectively. 
 
MRP-1 Expression 
MRP-1 specific staining was observed in 67.2% (90/134) of tumours analysed (Figure 
1(B) illustrates a typical example). 33% of all tumours did not express MRP-1 
protein. Independently assessing the primary tumours and metastases indicated MRP-
1 to be detected in 56.5% and 90.5% of cases, respectively. 
 
MDR1/P-gp and MRP-1 co-Expression 
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The expression of MDR1/P-gp and MRP-1 proteins were significantly associated 
(P=0.007). The majority (80.6%) of melanomas expressed at least one of the efflux 
pumps analysed; 44% expressed both, while only 19.4% expressed neither MDR1/P-
gp nor MRP-1 proteins (see Table 2(A)). For the primary tumour cohort alone, as 
summarised in Table 2(B), approximately 73% of cases expressed at least one of these 
pumps, 27% had neither MDR1/P-gp nor MRP-1, while 34% expressed both proteins. 
Table 2(C) indicates that the majority (97.6%) of the metastatic specimens expressed 
MDR1/P-gp and/or MRP-1; 67% had both. Almost a quarter (23.8%) of metastatic 
tumours had MRP-1, but lacked MDR1/P-gp expression, while only 7% expressed 
MDR1/P-gp alone. 
 
Overall, as shown in Table 3, a direct comparison of MDR1/P-gp and MRP-1 efflux 
pump expression in the primary versus the metastatic specimens indicated a 
significantly higher percentage of metastatic tumours, compared to primary tumours, 
expressed MDR1/P-gp (primary 50%; metastases 74%; P=0.010) and MRP-1 
(primary 57%; metastases 91%; P=<0.0001); with MRP-1 being the most prevalent 
efflux pump in these specimens. 
 
MDR1/P-gp and MRP-1 Expression in relation to clinicopathological features 
Using X2 analysis of the 134 population as a whole (summaried in Table 4), MDR1/P-
gp expression was found to be significantly (P=0.013) associated with lymph node 
positivity and tended to be associated with increased Breslow’s depth; however, in the 
latter case, statistical significance was approached (P=0.052). MRP-1 expression was 
also significantly associated with spread to lymph nodes (P<0.0005) and with more 
extensive invasion of the melanoma i.e. when comparing MRP-1 expression in 
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specimens with Clark’s level II, III and IV versus V; P=0.032 (incidentally, 
comparison of MRP-1 expression in those specimens with Clark’s levels II and III 
compared to IV and V also supported the association between MRP-1 expression and 
increasing stages of disease (although NS; P=0.051). 
 
Assessing expression of these efflux pumps in the cohort of primary tumours alone 
(Table 5) showed similar trends to those seen when evaluating all 134 cases i.e. 
MDR1/P-gp expression being associated with spread to lymph nodes (P=0.049) and 
increasing Breslow’s depth (although NS; P=0.056); with MRP-1 expression 
significantly associated with increasing Clark’s level (P=0.023).  
 
In relation to the metastases cohort alone, as the majority of these specimens 
expressed MRP-1 (~91%) and MDR1/P-gp (~74%), seeking association with 
clinicopathological factors is not relevant here. 
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DISCUSSION 
Malignant melanoma is one of the most challenging cancers to treat, resulting in 
highest per-death loss of years of potential life expectancy; with the exception of adult 
leukaemia (Seetharamu et al, 2009). Unfortunately the effectiveness of 
chemotherapeutic regimes evaluated in this cancer type is compromised and very 
limited due to the yet undefined highly resistant nature of this cancer.  
 
Drug efflux pumps, MDR1/P-gp and MRP-1, have been associated with chemo-
resistance in a number of cancer types. Studies of drug efflux pumps in melanoma 
have, however, been very limited to date. As outlined previously, studies of 
melanoma cell line models have resulted in conflicting results; some suggesting a role 
for MRP-1 (Berger et al, 1997), while others propose MDR1/P-gp to be potentially of 
more relevance (Molinari et al, 2000; Colone et al, 2008). Both earlier studies of 
melanoma tissue specimens (from 8 and 58 patients, evaluating mRNAs and proteins, 
respectively) reported MRP-1, but generally not MDR P-gp, expression (Ichihashi and 
Kitajima, 2001; Schadendorf et al, 1995). While those studies were important in 
highlighting the potential relevance of a drug efflux pump (namely, MRP-1) in 
melanoma, the numbers of specimens included were very limited. Furthermore, 
associations with patients’ clinical characteristics were not investigated. 
 
Here, in this more extensive study of 134 melanoma specimens, in agreement with the 
studies by Schadendorf et al (1995), we report MRP-1 protein to typically be 
expressed in melanoma. However, while Schadendorf et al (1995) reported the 
prevalence of expression to be the same in primary tumours and metastases, we 
observed that significantly higher percentages of metastatic specimens, compared to 
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primary tumours, express MRP-1. Furthermore, in contrast to the work reported by 
Schadendorf et al (1995) where MDR1/P-gp was detected in only 1 of 21 primary 
specimens and was absent from metastases, we detected MDR1/P-gp in more than 
half of the specimens analysed. As for MRP-1, expression of MDR1/P-gp was 
significantly more frequent in metastases compared to primary tumours. The 
discrepancies between our work and that reported by Schadendorf et al (1995) may, at 
least partly, be related to the larger cohort of specimens to which we had access for 
our analysis. We propose that such large studies could potentially contribute to more 
clinically relevant results.  
 
This, we believe, is the first study evaluating potential associations between MDR1/P-
gp and/or MRP-1 expression and melanoma patients’ clinicopathological 
characteristics. While we found no significant association between the presence of 
either efflux pump and the age or gender of the patients, we identified that the 
expression of these pumps tended to be associated with the more aggressive nature of 
melanoma. Specifically, MRP-1 expression was significantly associated with tumours 
classified as having a Clark’s level of V (i.e. invading to the subcutaneous fat, instead 
of being limited to the epidermal or dermal layers of the skin). Although statistical 
significance was not reached, MDR1/P-gp expression tended to be more strongly 
associated with tumours having a staging Breslow’s thickness of >4 mm; which, 
according to the AJCC guidelines, is prognostic of a 5 yrs. survival of approximately 
50%  (compared to 95-100% for <1 mm; 80-95% for 1-2 mm; and 60-80% for 2.1-4 
mm). Furthermore, we established that both MRP-1 and MDR1/P-gp expression are 
significantly associated with spread of cancer to the lymph nodes. The observed 
associations between expression of these efflux pumps and the more aggressive 
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phenotype of melanoma, together with the significantly higher prevalence of these 
pumps (MRP-1, in particular) in metastases compared to primary specimens, suggests 
that MRP-1 and MDR1/P-gp may contribute, at least to some extent, to the incurable 
nature of malignant melanoma. 
 
In conclusion, this study indicates that expression of drug efflux pumps, MRP-1 and 
MDR1/P-gp, is common in melanoma, especially in metastases, and so potentially 
could contribute to the chemo-resistant biology and thus incurable nature of this 
cancer type. The expression of these proteins – and, in particular, the predominant 
expression of MRP-1 – suggests that these pumps may be important contributors to 
this chemo-resistance. These findings suggest that the inhibition of multiple drug 
efflux pumps might be necessary if clinically relevant MDR reversal is to be achieved 
in malignant melanoma.  
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